- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2519EUR$2,750USD£2,144GBP
- Report
- August 2022
- 181 Pages
Global
From €6869EUR$7,500USD£5,848GBP
- Report
- February 2023
- 143 Pages
North America
From €3160EUR$3,450USD£2,690GBP
- Report
- January 2023
- 174 Pages
Global
From €4075EUR$4,450USD£3,470GBP
- Report
- November 2023
- 135 Pages
Global
From €3663EUR$4,000USD£3,119GBP
- Report
- February 2022
- 40 Pages
India
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
Saudi Arabia
From €1374EUR$1,500USD£1,170GBP
- Drug Pipelines
- April 2021
- 78 Pages
Global
€20148EUR$22,000USD£17,154GBP
- Report
- October 2018
- 17 Pages
Global
From €9158EUR$10,000USD£7,797GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- February 2022
- 80 Pages
Africa
From €1832EUR$2,000USD£1,559GBP
- Report
- February 2022
- 40 Pages
Brazil
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
China
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
France
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
Germany
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
Ireland
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
Japan
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
Russia
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
South Korea
From €1374EUR$1,500USD£1,170GBP
- Report
- February 2022
- 40 Pages
United States
From €1374EUR$1,500USD£1,170GBP

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon.
Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis.
The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more